

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: <b>Heinrich HAAS <i>et al.</i></b>	)	Confirmation No: <b>4615</b>
	)	
Application No. <b>10/584,296</b>	)	Art Unit: <b>1641</b>
	)	
Filed: <b>June 23, 2006</b>	)	Examiner: <b>K A Purdy</b>
	)	
For: <b>Loading of a camptothecin drug into colloidal nanoparticles</b>	)	Date: <b>August 13, 2008</b>

**INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(c)**

Pursuant to 37 C.F.R. 1.56 and 1.97(c), Applicants bring to the attention of the Examiner the documents listed on the attached PTO-1449. This Information Disclosure Statement is being filed to the best of the undersigned's knowledge before the mailing date of a Final Office Action or a Notice of Allowance for the above-referenced application.

To the best of the undersigned's knowledge, each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. A copy of the European Office Action dated June 9, 2008 which issued in a related European Patent Application (European Patent Application No. 04804274.1) is enclosed for the Examiner's consideration. Accordingly, Applicants do not believe that a fee is due with the filing of this paper.

A copy of document 2 is attached. Document 1 is a published U.S. Patent Application. Document 1 is listed as it is a translation of document 2. Applicants respectfully request that the Examiner initial and return the Form PTO-1449, indicating that the information has been considered and made of record herein.


This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." Applicants reserve the right to take appropriate action to establish the

patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

**Except** for issue fees payable under 37 C.F.R. 1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. 1.16 and 1.17 which may be required, including any required extension of time fees, or credit any overpayment to Deposit Account No. 50-0310. This paragraph is intended to be a **constructive petition for extension of time** in accordance with 37 C.F.R. 1.136(a)(3).

Dated: **August 13, 2008**  
Morgan, Lewis & Bockius LLP  
Customer No. **09629**  
1111 Pennsylvania Ave, N.W.  
Washington, D.C. 20004  
202-739-3000

Respectfully submitted,  
**Morgan, Lewis & Bockius LLP**

  
Sally P. Teng, Ph.D.  
Registration No. 45,397